Eledon Pharmaceuticals, Inc. ELDN
2.76 USD -0.11 (-3.83%)
At closeNov 10, 2026, 4:00 PM EST
2.76 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
2.67 Day range 2.84
1.35 52-week range 4.49
- YTD
- +82.78%
- 1 year
- +22.67%
News
benzinga.com Eledon Pharma Reports Improved Quality Of Life And Reduced Symptom Burden With Tegoprubart In Kidney Transplant Patients At ASN Kidney Week 2026 Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom
globenewswire.com Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom…
globenewswire.com Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of…
benzinga.com Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus…
benzinga.com Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026 Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus…
globenewswire.com Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus…
globenewswire.com Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of…
globenewswire.com Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes First patients enrolled in new investigator-initiated…
defenseworld.net 647,812 Shares in Eledon Pharmaceuticals, Inc. $ELDN Acquired by ADAR1 Capital Management LLC ADAR1 Capital Management LLC purchased a new position in Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) in the second quarter, according to the company in its most recent 13F filing with the SEC. The…
benzinga.com Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of…
globenewswire.com Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data…
seekingalpha.com Eledon: At The Center Of The Next Medical Frontier Eledon Pharmaceuticals (ELDN) is rated Buy, with tegoprubart showing strong promise post-Phase 2 in kidney transplantation and significant undervaluation versus risk-adjusted fair value. Tegoprubart…
benzinga.com This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
benzinga.com This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
benzinga.com Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12 Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million. China Pharma Holding (AMEX:CPHI) shares…- benzinga.com NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L…
- benzinga.com Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney Transplantation Eledon has established the regulatory framework for its Phase 3 kidney transplantation program and plans to initiate the trial in late 2026.Under the agreement, Natera’s Prospera test will serve as…
businesswire.com Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical…
seekingalpha.com Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation Transcript Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation Transcript
benzinga.com Eledon Pharma Announces New Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation, Presented At ATC 2026 Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61…
globenewswire.com Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart
zacks.com Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year? Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.- benzinga.com Eledon Pharmaceuticals Announces Updated Results From A Trial Evaluating Tegoprubart, Its Investigational Anti-CD40L Antibody; All 12 Patients Treated In The Study Showed Rapid Improvement In Glycemic Control Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of…
globenewswire.com Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine – All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D – All 12 patients also achieved an…- benzinga.com Eledon Pharmaceuticals To Present Updated Data From Investigator-Initiated Study At American Diabetes Association 86th Scientific Sessions Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant…
globenewswire.com Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions IRVINE, Calif. , June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at…
zacks.com Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year? Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
benzinga.com EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into human trials.- benzinga.com Eledon Pharma To Highlight New Clinical Data From Tegoprubart Program In Patients Undergoing Kidney Transplantation In Oral And Poster Presentation At ATC 2026 Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an…
globenewswire.com Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program in…
benzinga.com Eledon Pharma Q1 EPS $(0.33) Misses $(0.18) Estimate Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 312.5 percent decrease over losses of…
globenewswire.com Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights 100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug designation granted to…- benzinga.com Eledon Pharmaceuticals Files Prospectus For Offering $500M Securities https://www.sec.gov/Archives/edgar/data/1404281/000119312526201426/d79008ds3.htm
benzinga.com EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.- benzinga.com NewcelX Advances Diabetes Program With New Drug Partnership With Eledon Pharma To Prevent Transplant Rejection NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate…
globenewswire.com NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived…- benzinga.com Eledon Pharma Q4 EPS $(0.10) Beats $(0.18) Estimate Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.18) by 45.95 percent. This is a 84.38 percent increase over losses of…
benzinga.com Eledon Pharmaceuticals Says Investigator-Initiated Islet Transplant Trial Of Tegoprubart For Diabetes Shows 100% Insulin Independence Achieved In 10 Patients Who Are Over 4 Weeks Post-transplant Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from an investigator-initiated trial conducted at the University of Chicago Medicine Transplant Institute and…- benzinga.com Newcelx Announces Collaborative Research Agreement With Eledon Pharmaceuticals To Advance The NCEL-101 Program For Type 1 Diabetes The collaboration is designed to advance combination strategies integrating NewcelX's lead program, NCEL-101, with Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart (AT-1501), with…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Eledon Pharma To Present 24-Month Follow-Up Data From Eight Patients Enrolled In Phase 1b Trial Long-Term Extension Evaluating Tegoprubart In Kidney Transplantation At 2026 ASTS Winter Symposium Data from eight participants continue to support safety and tolerability profile of tegoprubartMean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2…
benzinga.com Eledon Pharmaceuticals Expects To Present 24-Month Data From 8 Participants In Phase 1 Extension Study Evaluating Tegoprubart In Kidney Transplantation In 2026; Report Other Data From Phase 1, 2 BESTOW Trials Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today announced a summary of 2025 accomplishments and provided guidance for anticipated upcoming 2026 business milestones.- benzinga.com Eledon Pharmaceuticals Data From First Six Participants Of Investigator-Initiated Study Of Anti-CD40 Ligand Demonstrates Marked Improvements In Glycemic Control Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine's Transplant Institute…
- benzinga.com Guggenheim Maintains Buy on Eledon Pharmaceuticals, Lowers Price Target to $8 Guggenheim analyst Vamil Divan maintains Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and lowers the price target from $9 to $8.
- benzinga.com Eledon Pharma Q3 EPS $(0.21) Beats $(0.24) Estimate Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 11.39 percent. This is a 25 percent increase over losses of $(0.28)…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Eledon Pharmaceuticals Launches ~$50M Offering Of 15.2M Common Shares At $1.65/Share; 15.2M Warrants At $1.649/Warrant Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares of its common stock at a public offering price of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Eledon Pharmaceuticals Reveals Proposed Underwritten Public Offering of Common Stock And Pre-Funded Warrants; Size Not Disclosed Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain…